Abu-Yousif AO, Cvet D, Gallery M, Bannerman BM, Ganno ML, Smith MD, Lai KC, Keating TA, Stringer B, Kamali A, Eng K, Koseoglu S, Zhu A, Xia CQ, Landen MS, Borland M, Robertson R, Bolleddula J, Qian MG, Fretland J, Veiby OP (2020) Preclinical antitumor activity and biodistribution of a novel anti-GCC antibody-drug conjugate in patient-derived xenografts. Mol Cancer Ther 19(10):2079–2088. https://doi.org/10.1158/1535-7163.MCT-19-1102
Krause WJ, Cullingford GL, Freeman RH, Eber SL, Richardson KC, Fok KF, Currie MG, Forte LR (1994) Distribution of heat-stable enterotoxin/guanylin receptors in the intestinal tract of man and other mammals. J Anat 184(Pt 2):407–417
Vaandrager AB (2002) Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol Cell Biochem 230(1–2):73–83
Han X, Mann E, Gilbert S, Guan Y, Steinbrecher KA, Montrose MH, Cohen MB (2011) Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS ONE 6(1):e16139. https://doi.org/10.1371/journal.pone.0016139
Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA (2007) Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133(2):599–607. https://doi.org/10.1053/j.gastro.2007.05.052
Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM (2007) Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol 171(6):1847–1858. https://doi.org/10.2353/ajpath.2007.070198
Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, Gao F, Trepicchio WL, Rugge M (2017) Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers. PLoS ONE 12(12):e0189953. https://doi.org/10.1371/journal.pone.0189953
Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA (2005) The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res 11(24 Pt 1):8549–8556. https://doi.org/10.1158/1078-0432.CCR-05-1624
Liu Y, Cheng G, Qian J, Ju H, Zhu Y, Stefano M, Keilholz U, Li D (2017) Expression of guanylyl cyclase C in tissue samples and the circulation of rectal cancer patients. Oncotarget 8(24):38841–38849. https://doi.org/10.18632/oncotarget.16406
Wolfe HR, Mendizabal M, Lleong E, Cuthbertson A, Desai V, Pullan S, Fujii DK, Morrison M, Pither R, Waldman SA (2002) In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C–specific ligand. J Nucl Med 43(3):392–399
Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK (1993) Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol Microbiol 8(5):865–873. https://doi.org/10.1111/j.1365-2958.1993.tb01633.x
Gallery M, Zhang J, Bradley DP, Brauer P, Cvet D, Estevam J, Danaee H, Greenfield E, Li P, Manfredi M, Loke HK, Rabino C, Stringer B, Williamson M, Wyant T, Yang J, Zhu Q, Abu-Yousif A, Veiby OP (2018) A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo. PLoS ONE 13(1):e0191046. https://doi.org/10.1371/journal.pone.0191046
Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, Danaee H, Asato T, Kalebic T, Wang H, Doi T (2018) TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study. Cancer Res Treat 50(2):398–404. https://doi.org/10.4143/crt.2017.074
Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, Jung J, Wyant T, Fasanmade AA, Messersmith W, Rodon J (2016) Phase I study of the investigational anti-guanylyl cyclase antibody-drug conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res 22(20):5049–5057. https://doi.org/10.1158/1078-0432.CCR-15-2474
Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, Lopez CM, Alsina M, Munoz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T (2017) Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs 35(2):235–241. https://doi.org/10.1007/s10637-017-0439-y
Miller ML, Shizuka M, Wilhelm A, Salomon P, Reid EE, Lanieri L, Sikka S, Maloney EK, Harvey L, Qiu Q, Archer KE, Bai C, Vitharana D, Harris L, Singh R, Ponte JF, Yoder NC, Kovtun Y, Lai KC, Ab O, Pinkas J, Keating TA, Chari RVJ (2018) A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody-drug conjugates (ADCs). Mol Cancer Ther 17(3):650–660. https://doi.org/10.1158/1535-7163.MCT-17-0940
European Medicines Agency (EMA). Enhertu (trastuzumab deruxtecan; EMA/692819/2020). https://www.ema.europa.eu/en/documents/overview/enhertu-epar-medicine-overview_en.pdf. Accessed Jan 2021
do Pazo C, Nawaz K, Webster RM (2021) The oncology market for antibody-drug conjugates. Nat Rev Drug Discov 20(8):583–584. https://doi.org/10.1038/d41573-021-00054-2
Scheving LA, Russell WE (1996) Guanylyl cyclase C is up-regulated by nonparenchymal cells and hepatocytes in regenerating rat liver. Cancer Res 56(22):5186–5191
Joubert N, Beck A, Dumontet C, Denevault-Sabourin C (2020) Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel) 13(9):245. https://doi.org/10.3390/ph13090245
留言 (0)